The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

GLP-1 medications like Ozempic show promise for multiple health conditions, as experts explore microdosing benefits for blood ...

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for ...

Novo Nordisk A/S is poised for long-term growth despite job cuts and margin resets. Click here to find out why NVO stock is a ...

The Chinese biotech will now pursue the further development of ASC30 in obesity for use as a maintenance and treatment ...

Cigna (CI) reports flat employer coverage rates for obesity drugs like Wegovy from Novo Nordisk (NVO) and Zepbound from Eli ...

After struggling to find relief, GLP-1s were the "miracle solution" to their PCOS symptoms. But without insurance coverage, ...

The Danish pharmaceutical company will reduce its 78,400-person workforce by approximately 9,000 positions to streamline ...

Novo Nordisk , the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to ...

Benefits consultants Aon and WTW told the Wall Street Journal that employer health-coverage costs are set to surge about 9.5% ...

Cigna said on Wednesday the percentage of employers paying for obesity drugs has remained flat year-over-year, though the health insurer still sees an uptick in demand for the wildly popular ...

The restructuring marks the first major action authorised by new CEO Mike Doustdar in a bid to turn the company’s fortunes ...